French company Flamel Technologies has added another high-profile
client for its drug delivery technology spurring another leap in
its shares that have already climbed almost 800 per cent over the
last 12 months.
Losses continue for buccal drug delivery company Generex
Biotechnology with the company yesterday reporting a net loss of
$4.6 million (€4.3m), or $(27) per share for the quarter ended
January 31, 2003 - compared to a net loss of...